Evolent Health - EVH Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVH shares.
View EVH analyst ratings or view top-rated stocks.

8 analysts have issued 12 month price objectives for Evolent Health's shares. Their EVH share price forecasts range from $40.00 to $55.00. On average, they anticipate the company's share price to reach $49.13 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price.
View analysts price targets for EVH or view top-rated stocks among Wall Street analysts.

Evolent Health's stock was trading at $27.67 on January 1st, 2022. Since then, EVH stock has increased by 32.8% and is now trading at $36.74.
View the best growth stocks for 2022 here.

Evolent Health saw a decrease in short interest in August. As of August 31st, there was short interest totaling 6,400,000 shares, a decrease of 24.3% from the August 15th total of 8,460,000 shares. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is currently 5.8 days.
View Evolent Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our EVH earnings forecast.

Evolent Health, Inc. (NYSE:EVH) posted its quarterly earnings data on Tuesday, August, 2nd. The technology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.07. The technology company earned $319.94 million during the quarter, compared to analysts' expectations of $293.31 million. Evolent Health had a positive trailing twelve-month return on equity of 0.41% and a negative net margin of 2.63%.

Evolent Health updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.32 billion-$1.36 billion, compared to the consensus revenue estimate of $1.22 billion.

12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

(EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVH stock can currently be purchased for approximately $36.74.

Evolent Health (NYSE:EVH) has a market capitalization of $3.37 billion and generates $907.96 million in revenue each year. The technology company earns $-37,600,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

The company employs 3,500 workers across the globe.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The official website for the company is www.evolenthealth.com. The technology company can be reached via phone at (571) 389-6000, via email at investorrelations@evolenthealth.com, or via fax at 571-389-6001.